Pharvaris Announces Annual Meeting of Shareholders
June 01, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023 06:50 ET
|
Pharvaris N.V.
Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 (immediate-release deucrictibant capsules) for the prophylactic treatment of HAE, anticipated by YE2023Executing from a strong...
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
May 06, 2023 13:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
April 05, 2023 06:51 ET
|
Pharvaris N.V.
Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated in 2H202326-week non-clinical toxicology study intended to address the...
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
March 18, 2023 00:35 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris to Present in Upcoming March Investor Conferences
March 02, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
February 24, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris to Present at SVB Securities Global Biopharma Conference
February 08, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
January 09, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
December 08, 2022 06:51 ET
|
Pharvaris N.V.
Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacksParticipated in a Type A meeting with the FDA regarding the previously...